Clinical trial Recruiting at 1 site Interventional Ages 21 and up

Improving colonoscopy follow-up for patients with high risk colon polyps

Official title: Multilevel Health System Intervention to Increase Guideline-Concordant Surveillance Colonoscopy for High Risk Colon Polyps

Run by Jonsson Comprehensive Cancer Center · NCT06376565 · Data updated 2026-11-12

This study is testing whether better reminders and support for scheduling can help patients with high risk colon polyps get their follow-up colonoscopies done on time to lower their chances of developing colorectal cancer.

Quick facts

Study typeInterventional
Ages21 Years and up
SexAll
Enrollment1680 (estimated)
SponsorJonsson Comprehensive Cancer Center
Academic / other
Locations1 site (Los Angeles, California)
StatusRecruiting
StartedNovember 8, 2023
Main results expectedNovember 30, 2027
Study endsNovember 30, 2027
Registry record updatedNovember 14, 2025
Trial IDNCT06376565 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are individuals aged 45 to 75 who have been diagnosed with high risk neoplasia within the past five years.

Probably not a fit

Patients with a personal history of colorectal carcinoma, inflammatory bowel disease, or polyposis syndrome may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial tests a multilevel intervention aimed at enhancing colonoscopy surveillance for patients diagnosed with high risk colon polyps. The study involves interviews with participants and randomization of primary care clinics into two groups: one receiving enhanced reminders and scheduling support for colonoscopy, and the other continuing with standard care practices. The primary goal is to increase the rate of completed surveillance colonoscopies within 3.5 years of high risk neoplasia diagnosis, thereby reducing the risk of colorectal cancer. The intervention includes automated health record updates, patient reminders, and proactive scheduling calls.

Why it matters

Potential benefit: If successful, this intervention could significantly improve the timely detection and prevention of colorectal cancer in high risk patients.

How similar studies have gone: Other studies have shown success with similar multilevel interventions aimed at improving cancer screening adherence, suggesting a promising approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* AIM 1 PATIENTS: Patients between age 45 and 75 with a HRN diagnosis in the past 5 years
* AIM 1 PATIENTS: 12 patients who did and 12 patients who did not have surveillance colonoscopy
* AIM 1 PROVIDERS: Primary care providers (PCPs) and gastroenterologists (GIs)
* AIM 1 ADMINISTRATORS: Administrators who are involved in care processes related to CRC screening, HRN surveillance, and/or colonoscopy scheduling
* AIM 2: Patients age 45 to 75 diagnosed with a HRN during the pre-specified two-year HRN diagnosis period

Exclusion Criteria:

* AIM 2: Individuals with a personal history of colorectal carcinoma (CRC), inflammatory bowel disease (Crohn's, ulcerative colitis), or polyposis syndrome
* AIM 2: HRN cases not confirmed by chart review (human-in-the-loop)

Where it's running

  • UCLA / Jonsson Comprehensive Cancer Center
    Los Angeles, California, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.